All In Biotech

Drug Trial Radar · NCT02515656

Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis

Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis International, Multicentre, Randomised, Double-blind, Parallel Group Study, Comparative Versus Miconazole

Last checked: Nov 19, 2026Latest source record: Jan 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 661 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

661

Actual

Start

Sep 2015

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Sponsor type
Industry
Collaborators
International Clinical Trials Association; Venn Life Sciences
First posted
Aug 5, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

POLYGYNAX® is a broad spectrum combination of nystatin, neomycin and polymixin B indicated for the local treatment of vaginitis due to sensitive germs and treatment of non specific vaginitis of adults. POLYGYNAX® has been marketed in France since 1969. Nevertheless, despite the well established use of POLYGYNAX®, there is no clinical study supporting the interest of the combination of antifungal and antibiotics agents versus antifungal agent alone. The aim of this project is to demonstrate that POLYGYNAX® is more effective than miconazole in the treatment of women experiencing symptoms of infectious vaginitis.

Conditions

  • Vaginitis

Interventions

  • POLYGYNAX®Drug

  • GYNODAKTARIN®Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment VisitTime frame: 15 days after first treatment administration

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • TURKOVA

    Prague, Czechia

  • PERCEVAL

    Lyon, France

  • MARICIC

    Belgrade, Serbia

  • GATOVA

    Martin, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.